Molecule

Pentec Health and Lobe Sciences Announce Exclusive Distribution Agreement, Initial Availability of Altemia, First U.S. Medical Food for People With Sickle Cell Disease

Retrieved on: 
Thursday, September 21, 2023
Molecule, Insurance, CSE, GLEN, DHA, SCD, Health, Health equity, Inherited disorders of trafficking, Research, Biomarker, History, Life expectancy, Pain, Pharmacist, Patient, Physician, Swelling, Nursing, Sickle cell disease, Mouse, Blood cell, Rare, Disease, Pharmaceutical industry, Dietary supplement, VOC, Lobe, Medicine

GLEN MILLS, Pa., Sept. 21, 2023 /PRNewswire-PRWeb/ -- Pentec Health, Inc. (Pentec) and Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") are pleased to announce an exclusive U.S. distribution agreement and the initial availability of Altemia™ – the first medical food in the U.S. designed specifically for children and adults with sickle cell disease (SCD).

Key Points: 
  • – Pentec Health, Inc. (Pentec) and Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") are pleased to announce an exclusive U.S. distribution agreement and the initial availability of Altemia™ – the first medical food in the U.S. designed specifically for children and adults with sickle cell disease (SCD).
  • (Pentec) and Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") are pleased to announce an exclusive U.S. distribution agreement and the initial availability of Altemia™ – the first medical food in the U.S. designed specifically for children and adults with sickle cell disease (SCD).
  • The initial availability of Altemia in select markets aligns with National Sickle Cell Awareness Month, which focuses on the need for research and treatment of SCD.
  • Dietary supplementation with docosahexanoic acid (DHA) increases red blood cell membrane flexibility in mice with sickle cell disease.

Accent Therapeutics Bolsters Leadership Team with Key Executive Hires

Retrieved on: 
Thursday, September 21, 2023
Molecule, Fulcrum, Amgen, American Chemical Society, Drug development, University, Weill Cornell Medicine, Marie Curie, Delta TechOps, Organic chemistry, CMC, Health, Cancer, Program management, Mentorship, Genentech, Tango, Dana–Farber Cancer Institute, Development, National Cancer Institute, Ribociclib, Johns Hopkins University, Novartis, Patient, Ruth, DHX9, MSI-H, Boston College, Therapy, IND, RWTH, Massachusetts Institute of Technology, Pharmaceutical industry, Accent, Chemistry, Sanofi, Research

LEXINGTON, Mass., Sept. 21, 2023 /PRNewswire/ -- Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced the appointments of Jason Sager, M.D., as Chief Medical Officer, Steven Mennen, Ph.D., as Vice President of Pre-Clinical Development and Stuart Ince, Ph.D. as Vice President of Program Leadership.

Key Points: 
  • "Our dedication to fortifying our team underscores the remarkable progress we've achieved as Accent advances its lead programs towards the clinic," said Shakti Narayan, Chief Executive Officer of Accent.
  • Together, Jason, Steven, and Stuart's combined experience will be immensely valuable as Accent moves towards becoming a clinical-stage company and bringing novel therapies to patients."
  • These key executive hires enhance Accent's positioning to potentially advance two investigational programs into the clinic.
  • Accent is also on track to begin IND-enabling studies for a second undisclosed program by the end of 2023.

Life Science: Cerba HealthCare to Acquire Canadian Contract Research Laboratory CIRION BioPharma Research to Expand Bioanalytical Capabilities and Shorten Time-to-Deploy Complex Clinical Trials

Retrieved on: 
Thursday, September 7, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Molecule, GLP, Drug development, College, Breeding, CAP, Clinical trial, Multimedia, Doctor of Philosophy, DSM-IV codes, Organization, CLIA, Medicine, IVD, Knowledge, Immunogenicity, ChromeOS, Medical device, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20230907759314/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230907759314/en/
    CIRION, a leading contract research organization has been operating global clinical trials over 30 years.
  • CIRION will rank under Cerba HealthCare’s business unit Cerba Research adding to its global network of cutting-edge laboratories in the Americas, Europe, Africa and Asia-Pacific.
  • Cerba Research CEO Mario Papillon said: “I see CIRION as a true strategic step in improving our offering both geographically and scientifically.
  • The CIRION scientists and experts are very excited to join Cerba Research in their continuous quest to provide the best possible solutions to serve and improve the clinical trials of our life science customers.”

Rapport Therapeutics Appoints Chief Operating Officer and Scientific Advisory Board Member

Retrieved on: 
Thursday, September 7, 2023
Mental Health, Health, Neurology, Research, Science, Pharmaceutical, Biotechnology, Molecule, Medicinal chemistry, Memorial Sloan Kettering Cancer Center, Senior, Samuel, Marketing, Ironwood Pharmaceuticals, Genomics, Journal of Medicinal Chemistry, Coronavirus Scientific Advisory Board, Multimedia, GV (company), Multiple sclerosis, Scio Diamond Technology Corporation, Genentech, Princeton University, BTK, Constipation, Genzyme, Chemistry, DSM-IV codes, Celera Corporation, Journal, Patient, Laboratory, Seizure, RAPS, American Cancer Society, Therapy, Pharmaceutical industry, Rapport, Boston College

Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of Cheryl Gault as Chief Operating Officer and Wendy Young, Ph.D., as a member of its Scientific Advisory Board.

Key Points: 
  • Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of Cheryl Gault as Chief Operating Officer and Wendy Young, Ph.D., as a member of its Scientific Advisory Board.
  • Ms. Gault comes to Rapport from Cyclerion Therapeutics, where she was Chief Operating Officer overseeing corporate and business development, portfolio strategy, new product planning and corporate strategy functions.
  • Ms. Gault also served at Genzyme Corporation in a variety of sales and marketing roles in the biosurgery division.
  • She currently serves on the boards of directors and scientific advisory boards of several biotech companies and is an advisor at Google Ventures.

Molecule Launches Bigbang, a New Data Lake Platform for Energy and Commodity Trading Organizations

Retrieved on: 
Thursday, September 7, 2023
Commodity, Growth, Risk management, Climate change, Energy, Risk, Data science, Video game, Fine chemical, Molecule, Big Bang (band)

HOUSTON, Sept. 7, 2023 /PRNewswire/ -- Molecule Software, the leader in modern cloud-based trading and risk management software for energy and commodities, announced the launch of Bigbang. Bigbang is a new data-lake-as-a-service platform that allows ETRM/CTRM users to automatically import trade data from Molecule and merge it with a variety of sources to query, analyze, and extract meaningful insights quickly and easily.

Key Points: 
  • As a New Data-Lake-as-a-Service Add-on to Molecule's Modern ETRM/CTRM Platform, Bigbang Ignites Deeper Data Insights for Energy and Commodity Traders.
  • As a value-add to Molecule, the Bigbang data lake platform empowers risk managers, quantitative analysts, and anyone who needs direct access to data in Molecule to perform complex queries on time-series data.
  • "We're seeing a growing need in the energy and commodities trading space for a turnkey data lake, as indicated by our own customers.
  • "Bigbang provides this much-needed functionality to Molecule users, allowing them to run more complex analyses of their trade data in Molecule.

Graticule Appoints Patrick Wulf Hanson as Chief Alliance Officer for EU Operations

Retrieved on: 
Tuesday, September 5, 2023
Data Management, Health, Technology, General Health, Research, Science, Molecule, Real, International, IQVIA, Internet, Multimedia, Parexel, Burson Cohn & Wolfe, Patient, Novo Nordisk, Corporate branding, Cohn, Management, EU, Luman Walters, Nordic

Graticule, a Real World Data CRO that conducts life science research and development projects with both USA and International data partners, is pleased to announce the onboarding of Patrick Hanson as the Chief Alliance Officer.

Key Points: 
  • Graticule, a Real World Data CRO that conducts life science research and development projects with both USA and International data partners, is pleased to announce the onboarding of Patrick Hanson as the Chief Alliance Officer.
  • View the full release here: https://www.businesswire.com/news/home/20230831939371/en/
    Daniel Poscover, Founder and CEO of Graticule, mentioned, “We are thrilled to welcome Patrick to our leadership team.
  • Before his industry work, Patrick held research and teaching positions in Sweden, Denmark, and the USA.
  • Patrick's vast network and diverse European experience will help introduce innovative business strategies and foster collaborations for Graticule's European operations.

Global Long Read Sequencing Market Research Report 2023-2030: Transformative Advantages, Clinical Applications, and Data Analysis Innovations - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 29, 2023
Biotechnology, Technology, Manufacturing, Health, Pharmaceutical, Other Science, Research, Other Manufacturing, Nanotechnology, Genetics, Science, Molecule, DNA, Workflow, Prevalence, Single-molecule real-time sequencing, SARS-CoV-2, Coronavirus, COVID-19, DSM-IV codes, Genomics, USD, Proteomics, LRS, SMRT, Traction, Investment, Application, Nanopore sequencing, Map, WGS, Nanopore, Knowledge, Oxford Nanopore Technologies, D, Speciality chemicals, Pharmaceutical industry, Vaccine, Medical imaging, Antibiotics, Fine chemical

The "Long Read Sequencing Market Size, Share & Trends Analysis Report By Product, By Technology (Nanopore Sequencing), By Workflow, By Application, By End-Use, By Region And Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Long Read Sequencing Market Size, Share & Trends Analysis Report By Product, By Technology (Nanopore Sequencing), By Workflow, By Application, By End-Use, By Region And Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global long read sequencing market size is expected to reach USD 3.78 billion by 2030, registering a CAGR of 30.92%
    In the realm of pharmaceutical modification, the significance of sequencing methods has never been more pronounced, underscored by the growing market value attributed to the expanding knowledge of long read sequencing.
  • Against this backdrop, ongoing research activities not only offer manufacturers a competitive edge in crafting advanced elongated read sequencing but also pave the way for an array of unexplored opportunities within the long read sequencing market.
  • In addition, the limitations of clinical disease research based on next-generation sequencing could be partially overcome by these technologies.

Reviva Reports Second Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Monday, August 14, 2023
Molecule, Central nervous system, Schizophrenia, ISID, ATS, Hosting, Research, CNS, Psoriasis, American Thoracic Society, DSM-IV codes, Patient, International Society for Bipolar Disorders, IPF, OLE, Idiopathic pulmonary fibrosis, Bipolar disorder, Pharmacology, Inflammation, ASPET, Pharmaceutical industry, Nursing, Cryptocurrency

CUPERTINO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing new therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometablolic diseases, today reported financial results for the second quarter ended June 30, 2023 and summarized recent business highlights.

Key Points: 
  • CUPERTINO, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing new therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometablolic diseases, today reported financial results for the second quarter ended June 30, 2023 and summarized recent business highlights.
  • “Brilaroxazine continues to demonstrate a well-tolerated safety profile with a unique potential to improve multiple symptom domains and neuroinflammation in schizophrenia.
  • As of June 30, 2023, the Company’s cash totaled approximately $11.2 million compared to approximately $18.5 million as of December 31, 2022.
  • Reviva believes that based on the current operating plan and financial resources, the Company’s cash as of June 30, 2023 will be sufficient to fund current operating plans well into the fourth quarter of 2023.

Alltrna Expands Leadership Team with Appointments of Chief Scientific Officer and Chief Technology Officer

Retrieved on: 
Tuesday, August 15, 2023
Molecule, Columbia University, Medicinal chemistry, University, Pasteur Institute, Duke University, Dimethyl fumarate, Therapy, Spinal muscular atrophy, Small RNA, Disease, Development, Biogen, University of Cambridge, CMC, Coronavirus Scientific Advisory Board, Research, RNA, Multiple sclerosis, Movement disorder, Chemistry, DSM-IV codes, Publication, Flagship Pioneering, Pasteur Institute of Iran, Ophthalmology, Biology, Entrepreneurship, SVP, Nusinersen, Rest, ALS, Management, Pharmaceutical industry, Trophos

Dr. Henderson was formerly Senior Vice President, Head of Research at Biogen, and Dr. Kiesman was Senior Vice President, CMC and Medicinal Chemistry at Alltrna.

Key Points: 
  • Dr. Henderson was formerly Senior Vice President, Head of Research at Biogen, and Dr. Kiesman was Senior Vice President, CMC and Medicinal Chemistry at Alltrna.
  • "Chris' deep scientific expertise and experience advancing programs into the clinic across a wide range of disease areas will be invaluable.
  • Will has significantly advanced our internal medicinal chemistry programs and developed a flexible manufacturing strategy to scale and deliver engineered tRNAs.
  • Dr. Henderson has more than 90 scientific research publications and been an editor and reviewer for top-tier scientific journals.

Ginkgo Bioworks Announces Participation in UBS MedTech, Tools and Genomics Summit 2023

Retrieved on: 
Thursday, August 10, 2023
Molecule, DNA, UBS, NYSE, Drug discovery, Genomics, Medical device, Pharmaceutical industry

BOSTON, Aug. 10, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, announced today that management is scheduled to participate in a panel discussion titled "Generative AI & Innovation Across Drug Discovery, Molecule Synthesis, & Precision Medicine" at the UBS MedTech, Tools and Genomics Summit 2023 on Tuesday, August 15 at 2:00 p.m. Pacific Time.

Key Points: 
  • BOSTON, Aug. 10, 2023 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, announced today that management is scheduled to participate in a panel discussion titled "Generative AI & Innovation Across Drug Discovery, Molecule Synthesis, & Precision Medicine" at the UBS MedTech, Tools and Genomics Summit 2023 on Tuesday, August 15 at 2:00 p.m. Pacific Time.